Home MarketStrides Shasun Ltd.

Strides Shasun Ltd. Stock Info: As on 2017-07-25 15:59:58

Nse

1084.20

1.00(0.09%)
Change%
52 Week Range
848.00
24.00
1,274.70
3.00
Open1,088.95
Day's Range974.88 - 1,191.52
Value Traded (in ₹ Cr.) 14.85

Bse

1084.65

2.05(0.19%)
Change %
52 Week Range
848.50
24.00
1,259.00
3.00
Open1,088.20
Day's Range974.34 - 1,190.86
Value Traded (in ₹ Cr.) 2.49

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 27,798,384.00 31.09%
Mutual Funds/UTI 11,209,440.00 12.54%
FII 30,845,238.00 34.49%
Employee 0.00 0.00%
Public 11,902,841.00 13.31%
Government 0.00 0.00%
Others 5,999,622.00 6.71%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.41
Basic EPS (Rs.) 19.50
Cash EPS 29.87
BVPerShare Excl 350.93
Operating Revenue 246.62
PBDITPerShare 47.35
Dividend 4.00
NPPerShare 18.03
Current Ratio 2.06
Quick Ratio 1.77
PriceToBV 3.10
Earnings 0.01
PBDIT Margin 19.19
PBT Margin 8.59
NP Margin 7.30
Return On Assets 3.00
Retention Ratios 73.63
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,344.45
Total Expenses 2,129.99
EBITDA 423.02
PBT 189.29
PAT 161.07
Net Income 161.07
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,244.33
Total Expenses 1,082.98
EBITDA 106.21
PBT 108.08
PAT 108.97
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 89.35
Net worth 3,135.41
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 89.35
Net worth 3,135.40
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

561.7 555.25 1.16
543.6567.5

Abbott India Ltd.

4364.5 4525.9 -3.57
4451.14617

Ajanta Pharma Ltd.

1450.15 1441.6 0.59
1436.51496

Albert David Ltd.

335.3 331.15 1.25
318.05334.95

Alembic Ltd.

42.9 43.45 -1.27
39.4545.3

Alembic Pharmaceuticals Ltd.

543.2 545.25 -0.38
537.9578

Alkem Laboratories Ltd.

1830 1805.75 1.34
17251831
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

129.4 128.8 0.47
127134.9

Aarti Drugs Ltd.

564 552.6 2.06
541573.2

Aayush Food & Herbs Ltd.

46.1 46.1 0
44.6548.5

Abbott India Ltd.

4355 4508.6 -3.41
44624562.95

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 83.56
Cash from investing activities -1,064.38
Cash from financing activities 1,570.84
Net change in cash 591.96

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
SBI Blue Chip Fund 1.59%
SBI Magnum Midcap Fund 3.54%
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.66%
SBI Pharma Fund 9.67%
Tata Balanced Fund - Regular Plan 0.87%
Sundaram Select Midcap 0.96%

Hindustan Copper signs MoU with MIDHANI

Hindustan Copper Limited (HCL) has said that it has signed a Memorandum of Understanding (MoU) with Mishra Dhatu Nigam Limited (MIDHANI), a CPSE under the Ministry of Defence at HCL Corporate Office, Kolkata, on 22nd July 2017, for a joint collaboration in area of production of Copper Nickel tubes and related items. “This will promote Make in India Initiative and create significant business synergy for HCL & MIDHANI. The MoU was signed by Shri K. D. Diwan, CMD, HCL, and Dr D. K. Likhi, CMD, MIDHANI in presence of senior officers of HCL and MIDHANI,” the company said in a filing to the Bombay Stock Exchange. Hindustan Copper Limited (HCL), a public sector enterprise of the Government of India was incorporated on 9th November 1967. It has the distinction of being India's only vertically integrated copper producing company encompassing mining, beneficiation, smelting, refining and casting of refined copper metal. Meanwhile, shares of the company were trading at Rs 66.30 apiece, up 1.92 per cent from the previous close at 10:30 hours on BSE.

25-07-2017 10:22

Ashok Leyland bags order worth Rs 650 cr from KSRTC

Hinduja group flagship firm Ashok Leyland has said that it has bagged an order worth Rs 650 crore for 3,019 buses from Kerala State Road Transport Corporation (KSRTC). This order will fulfil requirements from KSRTC and its subsidiaries such as North Western Karnataka Road Transport Corporation (NWKRTC), Bangalore Metropolitan Transport Corporation (BMTC) and North Eastern Karnataka Road Transport Corporation (NEKRTC). The order includes models such as 210” WB, fully built 210’ WB chassis for Karnataka Saarige bus, fully built 222” WB for Rajahamsa bus, fully built non-AC sleeper coaches on 222” WB chassis and fully built Midi bus on 205” WB chassis. “One of the largest from a state transport undertaking, the order will be executed in the current financial year,” Ashok Leyland said in a filing to the Bombay Stock Exchange. Our ability to bring value to customers like KSRTC is a testament to our superior technology and innovation, combined with low costs, the company's Managing Director Vinod K Dasari said. Meanwhile, shares of the company were trading at Rs 104.65 apiece, up 0.58 per cent from the previous close at 09:59 hours on BSE.

25-07-2017 09:52

Lupin bags approval for Fluocinonide Topical Solution

Pharma Major Lupin Limited (Lupin) has said that it has received final approval for its Fluocinonide Topical Solution USP, 0.05 per cent from the United States Food and Drug Administration (FDA) to market a generic version of County Line Pharmaceuticals, LLC’s Fluocinonide Topical Solution USP, 0.05 per cent. “Lupin’s Fluocinonide Topical Solution USP, 0.05% is AT rated generic equivalent of County Line Pharmaceuticals, LLC’s Fluocinonide Topical Solution USP, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,” the company said in a filing to the Bombay Stock Exchange. Fluocinonide Topical Solution USP, 0.05% had US sales of USD 32.4 million (IMS MAT March 2017). Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment. Meanwhile, shares of the company were trading at Rs 1133 apiece, down 0.84 per cent from the previous close at 09:30 hours on BSE.

25-07-2017 09:23

Vodafone India-Idea Cellular merger deal gets CCI nod

The Competition Commission approved the merger of Vodafone India and Idea Cellular, said lawyers who worked on the deal, which will create the country's largest telecom operator, reported PTI. Shardul Amarchand Mangaldas and Co said the regulator has unconditionally approved merger of the telecommunications businesses of Vodafone India and its wholly-owned subsidiary Vodafone Mobile Services, with Idea Cellular. The USD 23 billion transaction is the largest transaction by value in the history of Indian M&A, it said in a statement. Shardul Amarchand Mangaldas and Co advised Vodafone India and Vodafone Mobile Services on the deal. According to the statement, the regulator carried out a comprehensive review of the transaction and concluded that there was no appreciable adverse effect on competition from the proposed merger. The CCI approval, within Phase 1, is a very welcome development for both the Indian M&A landscape and the telecom sector, and will serve to fuel more investment in capacity and coverage across a battling telecom sector in India, Shweta Shroff Chopra, Partner at Shardul Amarchand Mangaldas, said. Phase 1 refers to the deal being approved within 30 working days as provided by the Competition Act. Law firm Trilegal, which advised Idea Cellular on the competition law aspects, said the deal with Vodafone India has received CCI approval. The proposed merger involved a merger of two of the biggest telecom companies in India and will create the largest telecom player in India, creating significant efficiencies and synergies, Trilegal said in a separate statement. Getting approval within Phase I implies that the deal would not be subject to detailed scrutiny. Transactions where there are prima facie concerns that they would adversely impact competition are taken into Phase II for an in-depth scrutiny. Mergers and acquisitions beyond a certain threshold require approval of the Competition Commission of India (CCI), which keeps a tab on unfair business practices across sectors. The deal, announced in March this year, will create the country's largest mobile phone operator worth more than USD 23 billion with a 35 per cent market share. Post the transaction, Vodafone will own 45.1 per cent stake in the merged entity while the Aditya Birla group, Idea's parent, will have 26 per cent shareholding after paying Rs 3,874 crore cash for a 4.9 per cent stake. The remaining 28.9 per cent will be held by other shareholders.

25-07-2017 00:19

SIS India sets IPO band at Rs. 805-815

Security and Intelligence Services (India) Ltd (SIS) has set the price band of Rs. 805-815 per share for its initial public offering (IPO) through which it aims to raise up to Rs. 780 crore, sources said. The initial share-sale offer will open for public subscription on July 31 and close on August 2, merchant banking media reports said. The company provides security solutions and business support services to a wide range of customers across India and Australia. The IPO comprises fresh issue of shares worth Rs. 362.25 crore and an offer for sale of up to 51,20,619 shares by the existing shareholders. Net proceeds from the fresh issue will be utilised for repayment and pre-payment of a portion of certain outstanding indebtedness, funding working capital requirements and for general corporate purposes, as per the Draft Red Herring Prospectus (DRHP). According to the sources, the company is estimated to raise around Rs. 780 crore at the higher end of the price band. Axis Capital, ICICI Securities, IIFL Holdings, Kotak Mahindra Capital Company are global coordinators and book running lead managers to the issue. SBI Capital Markets, IDBI Capital Markets and Securities and Yes Securities (India) are merchant bankers to the issue. In January, SIS had received market regulator SEBI’s go ahead to float an initial public offer.

25-07-2017 00:14

Strides Shasun gets USFDA nod to launch allergy drug in US

Drug maker Strides Shasun on Monday said that it has received approval from the United States Food & Drug Administration (USFDA) for allergy drug Cetirizine Hydrochloride capsules, 10 mg. ‘This is the first approval for a Softgel product after the recent US FDA inspection at the Company’s Bangalore facility,” said Strides Shasun in a filing to the Bombay Stock Exchange. Cetirizine is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching. It works by blocking a Certain natural Substance (histamine) that your body makes during an allergic reaction. The company said that the US market for Cetirizine Hydrochloride Capsules (Softgel) is approximately USD 60 mln, with only one other generic player. The product will be manufactured at the company’s flagship facility at Bangalore and marketed by Strides Pharma Inc. in the US Market, it added.

24-Jul-2017 09:10 AM

Strides Shasun L - Press Release

Strides Shasun receives USFDA Approval for Cetirizine Softgel Capsules

24-Jul-2017 08:50 AM

Strides Shasun bags approval for Promethazine tablets

Leading pharma company, Strides Shasun has said that it has received approval from the USFDA for Promethazine Hydrochloride tablets USP, 12.5 Mg, 25 mg and 50 mg. According to the IMS data, the US market for Promethazine Hydrochloride tablets USP 12.5 mg, 25 mg and 50 mg is approximately USD 17 million. The product will be manufactured at the company flagship facility in Bangalore and marketed by Strides Pharma Inc. in the US market. “The tablets are used to prevent and treat nausea and vomiting related to the certain condition. It is also used to treat allergy symptoms such as rash, itching and runny nose,” the company said in a filing to the Bombay Stock Exchange. Strides Arcolab is an Indian pharmaceutical company, headquartered at Bangalore in southern India. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Meanwhile, shares of the company were trading at Rs 994 apiece, down 0.45 per cent from the previous close at 13:53 hours on BSE.

03-Jul-2017 01:47 PM

Strides Shasun L - Press Release

Strides Shasun receives USFDA Approval for Promethazine Hydrochloride Tablets

03-Jul-2017 08:41 AM

Strides Shasun L - Updates on Amalgamation/ Merger / Demerger

Update on 'Composite Scheme of Arrangement between Strides Shasun Limited ('Company') and SeQuent Scientific Limited and Solara Active Pharma Sciences Limited and their respective shareholders and creditors ('Scheme')

30-Jun-2017 07:01 PM

Strides Shasun L - Press Release

Strides Shasun receives USFDA Approval for Cetirizine Softgel Capsules

24-Jul-2017 08:50 AM

Strides Shasun L - Press Release

Strides Shasun receives USFDA Approval for Promethazine Hydrochloride Tablets

03-Jul-2017 08:41 AM

Strides Shasun L - Updates on Amalgamation/ Merger / Demerger

Update on 'Composite Scheme of Arrangement between Strides Shasun Limited ('Company') and SeQuent Scientific Limited and Solara Active Pharma Sciences Limited and their respective shareholders and creditors ('Scheme')

30-Jun-2017 07:01 PM

Corporate Details

About Management

2002 -Board approves for the allotment of 210,955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd. -Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route. -Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act. -Incorporates 'Strides Africa Ltd' at British Virgin Island with an authorised capital of US $ 200,000 as 100% wholly owned subsidiary. -Board decides to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations. 2003 -Nominates Mr Francis Pinto as the Director on the Board of the company. -Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems. -Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical products. -Changes in the Management: Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr Krishna Kumar Menon as COO. -Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company. -Strides inks MoU with Ribbon SRL for Cephalosporin 2004 -Major Fire occurs in Private Custom Bonded warehouse in Mexico -Strides Arcolab Limited has entered into a memorandum of understanding with BITS, Pilani for an ``off campus collaborative programme''. As part of the partnership, Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job. 2005 - Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets. -Strides Arcolab enters into an agreement for private placement issue - Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs -Strides acquires sterile manufacturing facility in Poland 2007 - Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets, an anti-HIV drug. Efavirenz, is the generic version of Bristol Myers Squibb's Sustiva, which helps in preventing the HIV virus from reproduction. - Strides Arcolab receives 2 more NDA approvals from US-FDA. 2008 - Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials. 2010 - Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been appointed as an Executive Director of the Company. 2011 -Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite -Strides announces First European Approval for Oncology Product -Strides Arcolab receives US FDA Nod to Commercialize First Liquid -StridesArcoL Update on acquisition of outstanding minority shareholding in Ascent Pharmahealth Limited -Strides Arcolab joins the Malaysian Bio-xcell Ecosystem 2012 -Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile -Strides Arcolab receives US FDA approval for Methotrexate Injection -Strides Arcolab Announces Health Canada Approval For Tobramycin Injection -Strides Arcolab acquires Sterile Formulations facility to expand core injectable biz -Strides collaborates with Gilead Sciences 2013 -Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet. - Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. - Strides announces WHO pre-qualification for Artemether + Lumifantrine . -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology. -Strides Arcolab - Re-branding Biotech Business as ''Stelis''. -Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market. 2014 -- Medicines for Malaria Venture announces collaborations with Cipla and Strides. -Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. - Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. -Strides Arcolab receives US FDA approval for Buspirone Tablets. -Strides Arcolab receives US FDA approval for Calcitriol Softgel. -Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. -Strides Arcolab to acquire Shasun Pharma in all stock deal. 2015 -Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc -Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc, -Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India "Virso" -Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug -Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company. -Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia. -Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy -Strides Arcolab Ltd has changed from its present name "Strides Arcolab Limited" to "Strides Shasun Limited" 2016 -Strides Shasun updates on "Acquisition of seven brands from Johnson & Johnson". -Strides Shasun update on "Acquisition of CNS divisions of erstwhile Ranbaxy". -"Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia". -"Strides Shasun to acquire controlling stake in Universal Corporation, Kenya". -"Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet". - "Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore".

Registered Office

201, Devavrata, Sector 17, Vashi

022-27895247,27893199,,      022-27892924,

info@stridesshasun.com

http://www.stridesarco.com

Registrar Details

Karvy Computershare Private Ltd.